Biomarin Pharmaceutical Inc (BMRN)
84.97
-0.20
(-0.23%)
USD |
NASDAQ |
Jun 25, 16:00
86.04
+1.07
(+1.26%)
After-Hours: 05:49
Biomarin Pharmaceutical Research and Development Expense (TTM): 779.91M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 779.91M |
| December 31, 2023 | 746.77M |
| September 30, 2023 | 713.27M |
| June 30, 2023 | 679.79M |
| March 31, 2023 | 660.62M |
| December 31, 2022 | 649.61M |
| September 30, 2022 | 637.95M |
| June 30, 2022 | 637.99M |
| March 31, 2022 | 640.90M |
| December 31, 2021 | 628.79M |
| September 30, 2021 | 624.37M |
| June 30, 2021 | 613.55M |
| March 31, 2021 | 634.58M |
| December 31, 2020 | 628.12M |
| September 30, 2020 | 644.26M |
| June 30, 2020 | 670.17M |
| March 31, 2020 | 673.67M |
| December 31, 2019 | 715.01M |
| September 30, 2019 | 717.58M |
| June 30, 2019 | 706.03M |
| March 31, 2019 | 695.97M |
| December 31, 2018 | 696.33M |
| September 30, 2018 | 689.55M |
| June 30, 2018 | 682.24M |
| March 31, 2018 | 649.70M |
| Date | Value |
|---|---|
| December 31, 2017 | 610.75M |
| September 30, 2017 | 617.39M |
| June 30, 2017 | 624.12M |
| March 31, 2017 | 648.12M |
| December 31, 2016 | 661.90M |
| September 30, 2016 | 662.78M |
| June 30, 2016 | 660.66M |
| March 31, 2016 | 651.52M |
| December 31, 2015 | 634.81M |
| September 30, 2015 | 600.76M |
| June 30, 2015 | 567.73M |
| March 31, 2015 | 517.53M |
| December 31, 2014 | 461.62M |
| September 30, 2014 | 416.87M |
| June 30, 2014 | 379.24M |
| March 31, 2014 | 357.20M |
| December 31, 2013 | 354.78M |
| September 30, 2013 | 341.83M |
| June 30, 2013 | 319.98M |
| March 31, 2013 | 312.13M |
| December 31, 2012 | 302.22M |
| September 30, 2012 | 275.76M |
| June 30, 2012 | 268.13M |
| March 31, 2012 | 243.23M |
| December 31, 2011 | 214.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
613.55M
Minimum
Jun 2021
779.91M
Maximum
Mar 2024
670.15M
Average
655.11M
Median
Research and Development Expense (TTM) Benchmarks
| Krystal Biotech Inc | 45.10M |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Ligand Pharmaceuticals Inc | 23.84M |
| Blueprint Medicines Corp | 406.04M |
| BridgeBio Pharma Inc | 503.82M |